NYSEAMERICAN:NSRX Nasus Pharma (NSRX) Stock Price, News & Analysis $2.74 +0.13 (+4.98%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsNews and TrendsSEC Filings About Nasus Pharma Stock (NYSEAMERICAN:NSRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nasus Pharma alerts:Sign Up Key Stats Today's Range$2.68▼$2.7450-Day Range$2.61▼$3.9252-Week Range$1.98▼$9.50Volume5,813 shsAverage Volume72,431 shsMarket Capitalization$32.09 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingBuy Company Overview Nasus Pharma is an Israel-based clinical-stage pharmaceutical company developing intranasal powder treatments intended for rapid use in emergency situations. Its platform is designed to deliver medicines through the nose without requiring an injection. The company’s development programs focus on rescue treatments for conditions including opioid overdose and seizures. Nasus Pharma is working to advance these products through development and evaluation; they are not established marketed therapies.AI Generated. May Contain Errors. Read More Nasus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreNSRX MarketRank™: 3.500466728895 of 5 starsNasus Pharma scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingNasus Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialNasus Pharma has a consensus price target of $12.50, representing about 378.9% upside from its current price of $2.61.Amount of Analyst CoverageNasus Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Nasus Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nasus Pharma are expected to grow in the coming year, from ($0.84) to ($0.81) per share.Price to Book Value per Share RatioNasus Pharma has a P/B Ratio of 8.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.61% of the float of Nasus Pharma has been sold short.Short Interest Ratio / Days to CoverNasus Pharma has a short interest ratio ("days to cover") of 3.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nasus Pharma has recently decreased by 11.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNasus Pharma does not currently pay a dividend.Dividend GrowthNasus Pharma does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.01 News SentimentNasus Pharma has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nasus Pharma this week, compared to 1 article on an average week.MarketBeat Follows4 people have added Nasus Pharma to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nasus Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsNasus Pharma has minimal institutional ownership at this time.Read more about Nasus Pharma's insider trading history. Receive NSRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nasus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NSRX Stock News HeadlinesNasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe ...November 17 at 11:33 AM | finance.yahoo.comNasus Pharma appoints Nir Sassi as CFONovember 16 at 12:59 PM | msn.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.November 18 at 1:00 AM | Profits Run (Ad)Nasus Pharma Appoints Nir Sassi as Chief Financial OfficerNovember 16 at 8:51 AM | tipranks.comNasus Pharma Appoints Nir Sassi as Chief Financial OfficerNovember 16 at 8:00 AM | globenewswire.comNasus Pharma consensus price target decreased by 25.42% to $14.96November 2, 2026 | msn.comMaxim Group initiates coverage of Nasus Pharma with buyOctober 30, 2026 | msn.comNasus Pharma Ltd (NSRX)October 20, 2026 | investing.comSee More Headlines NSRX Stock Analysis - Frequently Asked Questions How have NSRX shares performed this year? Nasus Pharma's stock was trading at $7.10 at the start of the year. Since then, NSRX stock has decreased by 63.2% and is now trading at $2.61. How do I buy shares of Nasus Pharma? Shares of NSRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/17/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NSRX's financial health is in the Green zone, according to TradeSmith. NSRX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:NSRX CIK2029039 Webwww.nasuspharma.com Phone972-3573-6632FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Nasus Pharma$12.50 High Price Target$18.00 Low Price Target$7.00 Potential Upside/Downside+356.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.77 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book8.84Miscellaneous Outstanding Shares11,710,000Free FloatN/AMarket Cap$32.09 million OptionableN/A Beta4.25 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NYSEAMERICAN:NSRX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nasus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nasus Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.